Key facts
- This page summarizes David Arkowitz's Form 4 filing for Seres Therapeutics, Inc. (MCRB).
- 6 reported transactions and 4 derivative rows are listed below.
- Accepted by SEC: 16 Feb 2024, 21:13.
David Arkowitz - 14 Feb 2024 Form 4 Insider Report for Seres Therapeutics, Inc. (MCRB)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- MCRB
- Reported as of
- 14 Feb 2024
- Net transaction value
- -$4,254
- SEC form
- 4
- Accepted by SEC
- 16 Feb 2024, 21:13:51 UTC
- Prior SEC filing
- 31 Oct 2023
- Next SEC filing
- 05 Sep 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Thomas J. DesRosier, attorney-in-fact for David Arkowitz
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
David Arkowitz filed Form 4 for Seres Therapeutics, Inc. (MCRB) on 16 Feb 2024.
Change
- Previous filing in this sequence was filed on 31 Oct 2023.
- Current net transaction value: -$4,254.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MCRB
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +10,625
- Change %
- +6%
- Price
- Shares after
- 186,381
- Date
- 15 Feb 2024
- Ownership
- Direct
- Footnotes
- F1
MCRB
transaction
Common Stock
Sale
- Transaction value
- $4,254
- Shares
- -3,939
- Change %
- -2.1%
- Price
- $1.08
- Shares after
- 182,442
- Date
- 16 Feb 2024
- Ownership
- Direct
- Footnotes
- F2, F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MCRB
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +213,750
- Change %
- Price
- $0.000000
- Shares after
- 213,750
- Date
- 14 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 213,750
- Exercise price
- $1.10
- Footnotes
- F4
MCRB
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +287,905
- Change %
- Price
- $0.000000
- Shares after
- 287,905
- Date
- 14 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 287,905
- Exercise price
- $1.10
- Footnotes
- F5
MCRB
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +35,625
- Change %
- Price
- $0.000000
- Shares after
- 35,625
- Date
- 14 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 35,625
- Exercise price
- Footnotes
- F1, F6
MCRB
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -10,625
- Change %
- -25%
- Price
- $0.000000
- Shares after
- 31,875
- Date
- 15 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 10,625
- Exercise price
- Footnotes
- F1, F7
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 7 footnotes
Footnote F1
Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
Footnote F2
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.
Footnote F3
The price reported in column 4 is a weighted average of the price. These shares were sold in multiple transactions at prices ranging from $1.08 to $1.115, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F4
The option will vest as to 25% of the shares on February 14, 2025. The remainder of the shares will vest in 12 equal quarterly installments thereafter.
Footnote F5
The option will vest, if at all, in two substantially equal installments upon achievement of a 30-day trailing average public market closing price per share of the Issuer's common stock greater than or equal to $3.00 and $5.00, respectively.
Footnote F6
The restricted stock units will vest and settle as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.
Footnote F7
The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.